EMA's committee starts review of depression and anxiety medicine Deanxit after reports of serious side effects
03 November 2026 by Wendy WINN (DG SANTE, European Commission)The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of Deanxit (flupentixol/melitracen), a fixed-dose combination medicine for treating depression and anxiety, following reports of serious neurological and psychiatric side effects in patients...